Virtus LifeSci Biotech Clinical Trials ETF
21 hedge funds and large institutions have $19M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1.2% less ownership
Funds ownership: 41.56% → 40.35% (-1.2%)
Holders
21
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$223K | |
| 2 | +$210K | |
| 3 | +$169K | |
| 4 |
LPL Financial
San Diego,
California
|
+$124K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$103K |
Top Sellers
| 1 | -$1.54M | |
| 2 | -$511K | |
| 3 | -$177K | |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$177K |
| 5 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$56.2K |